Elmind Capital LP Makes New $994,000 Investment in Supernus Pharmaceuticals, Inc. $SUPN

Elmind Capital LP acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 20,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $994,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp grew its holdings in shares of Supernus Pharmaceuticals by 1.4% during the fourth quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock valued at $110,296,000 after buying an additional 31,668 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock valued at $73,215,000 after buying an additional 62,875 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Supernus Pharmaceuticals by 12.7% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after buying an additional 162,905 shares during the last quarter. Stephens Investment Management Group LLC grew its holdings in shares of Supernus Pharmaceuticals by 4.5% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after buying an additional 61,120 shares during the last quarter. Finally, Woodline Partners LP grew its holdings in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after buying an additional 490,835 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SUPN. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $43.58 on Thursday. The company has a market capitalization of $2.53 billion, a price-to-earnings ratio of -85.45, a PEG ratio of 0.93 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a one year low of $30.83 and a one year high of $59.68. The company’s fifty day moving average price is $48.27 and its 200-day moving average price is $49.51.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.